Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of OCT2/OCTN1 Polymorphisms on Gabapentin PK
NCT02977208Phase 4Completed
- Sponsor
- Universidade Estadual Paulista
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gabapentin in epilepsy and chronic pain (2 arms), sponsored by Universidade Estadual Paulista. Primary endpoints: Gabapentin plasma concentration and OCT2 and OCTN1 genotyping. Started Sep 2016; status: completed.
02
Drugs
gabapentin
03
Conditions
epilepsychronic pain
Beyond the preview
Go deeper on NCT02977208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977208.